Monocyte-derived dendritic cells with silenced PD-1 ligands and transpresenting interleukin-15 stimulate strong tumor-reactive T-cell expansion

Cancer Immunology Research

Volumn 5, Issue 8, 2017, Pages 710-715

  Van Den Bergh, Johan M J ^a   Smits, Evelien L J M ^a   Berneman, Zwi N ^a   Hutten, Tim J A ^b   De Reu, Hans ^a   Van Tendeloo, Viggo F I ^a   Dolstra, Harry ^b   Lion, Eva ^a   Hobo, Willemijn ^b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR; CANCER VACCINE; CD274 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOID LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; EX VIVO STUDY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MONOCYTE; MYELODYSPLASTIC SYNDROME; PROTEIN EXPRESSION; REFRACTORY ANEMIA WITH EXCESS BLASTS; T LYMPHOCYTE; ALLOTRANSPLANTATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; GRAFT VERSUS TUMOR EFFECT; IMMUNOLOGY; STEM CELL TRANSPLANTATION; TRANSPLANTATION; VACCINATION;

B7-H1 ANTIGEN; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; GRAFT VS TUMOR EFFECT; HUMANS; INTERLEUKIN-15; MONOCYTES; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; PROGRAMMED CELL DEATH 1 RECEPTOR; RNA, SMALL INTERFERING; STEM CELL TRANSPLANTATION; TRANSFECTION; TRANSPLANTATION, HOMOLOGOUS; VACCINATION;

EID: 85026515388     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-16-0336     Document Type: Article

References (26)

1. Cancer Research Institute. 2016 http://www.cancerresearch.org/our-strategyimpact/timeline-of-progress/timeline-detail.
2. Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol 2014;15:e257–67.
3. Elster JD, Krishnadas DK, Lucas KG. Dendritic cell vaccines: A review of recent developments and their potential pediatric application. Human Vaccines Immunother 2016;12:2232–9.
4. Van den Bergh JM, Van Tendeloo VF, Smits EL. Interleukin-15: new kid on the block for antitumor combination therapy. Cytokine Growth Factor Rev 2015;26:15–24.
5. Hurwitz AA, Lee S, Knox S, Kohrt H, Verdeil G, Romano E, et al. 29th Annual meeting of the society for immunotherapy of cancer (SITC). J Immunother Cancer 2015;3.
6. Burkett PR, Koka R, Chien M, Chai S, Boone DL, Ma A. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8þ T cell homeostasis. J Exp Med 2004;200:825–34.
7. Schluns KS, Stoklasek T, Lefrancois L. The roles of interleukin-15 receptor alpha: trans-presentation, receptor component, or both? Int J Biochem Cell Biol 2005;37:1567–71.
8. Van den Bergh J, Willemen Y, Lion E, Van Acker H, De Reu H, Anguille S, et al. Transpresentation of interleukin-15 by IL-15/IL-15Ralpha mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity. Oncotarget 2015;6:44123–33.
9. Li Y, Li F, Jiang F, Lv X, Zhang R, Lu A, et al. A mini-review for cancer immunotherapy: molecular understanding of PD-1/PD-L1 pathway & translational blockade of immune checkpoints. Int J Mol Sci 2016;17.
10. Roeven MW, Hobo W, van der Voort R, Fredrix H, Norde WJ, Teijgeler K, et al. Efficient nontoxic delivery of PD-L1 and PD-L2 siRNA into dendritic cell vaccines using the cationic lipid SAINT-18. J Immunother 2015; 38:145–54.
11. Hobo W, Maas F, Adisty N, de Witte T, Schaap N, van der Voort R, et al. siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8þ T cells. Blood 2010;116:4501–11.
12. Hobo W, Broen K, van der Velden WJ, Greupink-Draaisma A, Adisty N, Wouters Y, et al. Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2013;19:274–82.
13. Spierings E, Kim YH, Hendriks M, Borst E, Sergeant R, Canossi A, et al. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013;19:1244–53.
14. van der Waart AB, Fredrix H, van der Voort R, Schaap N, Hobo W, Dolstra H. siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(þ) T cells in NOD/SCID/IL2Rg(null) mice. Cancer Immunol Immunother 2015; 64:645–54.
15. Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 2008;105:11915–20.
16. Hobo W, Novobrantseva TI, Fredrix H, Wong J, Milstein S, Epstein-Barash H, et al. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol Immunother 2013;62:285–97.
17. Barrett AJ, Battiwalla M. Relapse after allogeneic stem cell transplantation. Expert Rev Hematol 2010;3:429–41.
18. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012;12:265–77.
19. Morris JC, Ramlogan-Steel CA, Yu P, Black BA, Mannan P, Allison JP, et al. Vaccination with tumor cells expressing IL-15 and IL-15Ralpha inhibits murine breast and prostate cancer. Gene Ther 2014;21:393–401.
20. Muenst S, Soysal SD, Tzankov A, Hoeller S. The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy. Expert Opin Ther Targets 2015;19:201–11.
21. Guo Y, Luan L, Rabacal W, Bohannon JK, Fensterheim BA, Hernandez A, et al. IL-15 superagonist-mediated immunotoxicity: role of NK cells and IFN-gamma. J Immunol 2015;195:2353–64.
22. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016;54:139–48.
23. Van den Bergh JM, Lion E, Van Tendeloo VF, Smits EL. IL-15 receptor alpha as the magic wand to boost the success of IL-15 antitumor therapies: the upswing of IL-15 transpresentation. Pharmacol Thera 2017;170: 73–9.
24. Banchereau J, Thompson-Snipes L, Zurawski S, Blanck JP, Cao Y, Clayton S, et al. The differential production of cytokines by human Langerhans cells and dermal CD14(þ) DCs controls CTL priming. Blood 2012; 119:5742–9.
25. Romano E, Cotari JW, Barreira da Silva R, Betts BC, Chung DJ, Avogadri F, et al. Human Langerhans cells use an IL-15R-alpha/IL-15/pSTAT5-depen-dent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1. Blood 2012;119:5182–90.
26. van der Waart AB, van de Weem NM, Maas F, Kramer CS, Kester MG, Falkenburg JH, et al. Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy. Blood 2014;124:3490–500.